Refametinib
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric MEK1/MEK2 inhibitor with IC50s of 19 nM and 47 nM, respectively.
Product Specifications
CAS Number
[923032-37-5]
Product Name Alternative
BAY 869766; RDEA119
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
MEK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Refametinib.html
Purity
99.82
Solubility
DMSO : ≥ 31 mg/mL
Smiles
O=S(C1(C[C@H](O)CO)CC1)(NC(C(NC(C(F)=C2)=CC=C2I)=C3F)=C(OC)C=C3F)=O
Molecular Formula
C19H20F3IN2O5S
Molecular Weight
572.34
Precautions
H302, H315, H319, H335
References & Citations
[1]Iverson C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69 (17) :6839-47.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
MEK1; MEK2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
